Quercetin and rutin reduced the bioavailability of cyclosporine from Neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4

Journal of Agricultural and Food Chemistry

Volumn 59, Issue 9, 2011, Pages 4644-4648

  Yu, Chung Ping ^a   Wu, Ping Ping ^a   Hou, Yu Chi ^a,b   Lin, Shiuan Pey ^a   Tsai, Shang Yuan ^a   Chen, Chiung Tong ^c   Chao, Pei Dawn Lee ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Bioavailability; Cyclosporine; CYP 3A4; P gp; Quercetin; Rutin

Indexed keywords

BIOAVAILABILITY; CYCLOSPORINE; CYP 3A4; P-GP; QUERCETIN; RUTIN;

ALCOHOLS; BIOCHEMISTRY; FATTY ACIDS; GLYCOPROTEINS; PATIENT MONITORING;

PHENOLS;

CYCLOSPORIN; CYTOCHROME P450 3A; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; QUERCETIN; RUTOSIDE;

ANIMAL; ARTICLE; BIOAVAILABILITY; CHEMISTRY; DRUG ANTAGONISM; DRUG SCREENING; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; RAT; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DRUG ANTAGONISM; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; P-GLYCOPROTEIN; QUERCETIN; RATS; RATS, SPRAGUE-DAWLEY; RUTIN;

RATTUS;

EID: 79955703687     PISSN: 00218561     EISSN: 15205118     Source Type: Journal    
DOI: 10.1021/jf104786t     Document Type: Article

References (38)

1. Hertog,M.G.;Kromhout,D.;Aravanis,C.;Blackburn,H.;Buzina,R.; Fidanza, F.; Giampaoli, S.; Jansen, A.; Menotti, A.; Nedeljkovic, S.; et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch. Intern. Med. 1995, 155 (4), 381-386.
2. Brand, W.; Schutte, M. E.; Williamson, G.; van Zanden, J. J.; Cnubben, N. H.; Groten, J. P.; van Bladeren, P. J.; Rietjens, I. M. Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients. Biomed. Pharmacother. 2006, 60 (9), 508-519. (Pubitemid 44635082)
3. Moon, Y. J.; Wang, X.; Morris, M. E. Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism. Toxicol. in Vitro 2006, 20 (2), 187-210. (Pubitemid 43087702)
4. Horvathova, K.; Novotny, L.; Vachalkova, A. The free radical scavenging activity of four flavonoids determined by the comet assay. Neoplasma 2003, 50 (4), 291-295. (Pubitemid 37128063)
5. Park, Y. C.; Rimbach, G.; Saliou, C.; Valacchi, G.; Packer, L. Activity of monomeric, dimeric, and trimeric flavonoids on NO production, TNF-alpha secretion, and NF-kappaB-dependent gene expression in RAW 264.7 macrophages. FEBS Lett. 2000, 465 (2-3), 93-97. (Pubitemid 30021451)
6. Birt, D. F.; Hendrich, S.; Wang, W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol. Ther. 2001, 90 (2-3), 157-177. (Pubitemid 32913477)
7. Ramos, S. Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. J. Nutr. Biochem. 2007, 18 (7), 427-442. (Pubitemid 46874924)
8. Murakami, A.; Ashida, H.; Terao, J. Multitargeted cancer prevention by quercetin. Cancer Lett. 2008, 269 (2), 315-325.
9. Jeong, J. H.; An, J. Y.; Kwon, Y. T.; Rhee, J. G.; Lee, Y. J. Effects of low dose quercetin: cancer cell-specific inhibition of cell cycle progression. J. Cell. Biochem. 2009, 106 (1), 73-82.
10. Baba, S.; Furuta, T.; Fujioka, M.; Goromaru, T. Studies on drug metabolism by use of isotopes XXVII: urinary metabolites of rutin in rats and the role of intestinal microflora in the metabolism of rutin. J. Pharm. Sci. 1983, 72 (10), 1155-1158. (Pubitemid 13013630)
11. Kim, D. H.; Jung, E. A.; Sohng, I. S.; Han, J. A.; Kim, T. H.; Han, M. J. Intestinal bacterial metabolism of flavonoids and its relation to some biological activities. Arch. Pharm. Res. 1998, 21 (1), 17-23. (Pubitemid 128668375)
12. Ma, S. Quercetin not only inhibits P-glycoprotein efflux activity but also inhibits CYP3A isozymes. Cancer Chemother. Pharmacol. 1995, 36 (5), 448-450.
13. Mitsunaga, Y.; Takanaga, H.; Matsuo, H.; Naito, M.; Tsuruo, T.; Ohtani, H.; Sawada, Y. Effect of bioflavonoids on vincristine transport across blood-brain barrier. Eur. J. Pharmacol. 2000, 395 (3), 193-201. (Pubitemid 30254368)
14. Di Pietro, A.; Conseil, G.; Perez-Victoria, J. M.; Dayan, G.; Baubichon-Cortay, H.; Trompier, D.; Steinfels, E.; Jault, J. M.; de Wet, H.; Maitrejean, M.; Comte, G.; Boumendjel, A.; Mariotte, A. M.; Dumontet, C.; McIntosh, D. B.; Goffeau, A.; Castanys, S.; Gamarro, F.; Barron, D. Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell. Mol. Life Sci. 2002, 59 (2), 307-322. (Pubitemid 34169516)
15. Burke, J. F., Jr.; Pirsch, J. D.; Ramos, E. L.; Salomon, D. R.; Stablein, D. M.; Van Buren, D. H.; West, J. C. Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N. Engl. J. Med. 1994, 331 (6), 358-363. (Pubitemid 24233855)
16. Edwards, D. J.; Fitzsimmons, M. E.; Schuetz, E. G.; Yasuda, K.; Ducharme, M. P.; Warbasse, L. H.; Woster, P. M.; Schuetz, J. D.; Watkins, P. 6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: Effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin. Pharmacol. Ther. 1999, 65 (3), 237-244. (Pubitemid 29142929)
17. Goralski, K. B.; Acott, P. D.; Fraser, A. D.; Worth, D.; Sinal, C. J. Brain cyclosporin A levels are determined by ontogenic regulation of mdr1a expression. Drug Metab. Dispos. 2006, 34 (2), 288-295. (Pubitemid 43145030)
18. Choc, M. G. Bioavailability and pharmacokinetics of cyclosporine formulations: Neoral vs Sandimmune. Int. J. Dermatol. 1997, 36 (Suppl. 1), 1-6. (Pubitemid 28060180)
19. Ritschel, W. A. Microemulsion technology in the reformulation of cyclosporine: The reason behind the pharmacokinetic properties of Neoral. Clin. Transplant. 1996, 10 (4), 364-373. (Pubitemid 26300748)
20. Min, D. I. Neoral: A microemulsion cyclosporine. J. Transpl. Coord. 1996, 6 (1), 5-8. (Pubitemid 26332269)
21. Friman, S.; Backman, L. A new microemulsion formulation of cyclosporin: Pharmacokinetic and clinical features. Clin. Pharmacokinet. 1996, 30 (3), 181-193.
22. Hsiu, S. L.; Hou, Y. C.; Wang, Y. H.; Tsao, C. W.; Su, S. F.; Chao, P. D. Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats. Life Sci. 2002, 72 (3), 227-235.
23. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65 (1-2), 55-63. (Pubitemid 14203433)
24. Jia, J. X.; Wasan, K. M. Effects of monoglycerides on rhodamine 123 accumulation, estradiol 17 beta-D-glucuronide bidirectional transport and MRP2 protein expression within Caco-2 cells. J. Pharm. Pharm. Sci. 2008, 11 (3), 45-62.
25. Yang, C. Y.; Hsiu, S. L.; Wen, K. C.; Lin, S. P.; Tsai, S. Y.; Hou, Y. C.; Chao, P. D. L. Bioavailability and metabolic pharmacokinetics of rutin and quercetin in rats. J. Food Drug Anal. 2005, 13, 244-250.
26. Yang, C. Y.; Chao, P. D.; Hou, Y. C.; Tsai, S. Y.; Wen, K. C.; Hsiu, S. L. Marked decrease of cyclosporin bioavailability caused by coadministration of ginkgo and onion in rats. Food Chem. Toxicol. 2006, 44 (9), 1572-1578. (Pubitemid 43994271)
27. Erlund, I.; Kosonen, T.; Alfthan, G.; Maenpaa, J.; Perttunen, K.; Kenraali, J.; Parantainen, J.; Aro, A. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur. J. Clin. Pharmacol. 2000, 56 (8), 545-553.
28. Karliova, M.; Treichel, U.; Malago, M.; Frilling, A.; Gerken, G.; Broelsch, C. E. Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation. J. Hepatol. 2000, 33 (5), 853-855.
29. Ruschitzka, F.; Meier, P. J.; Turina, M.; Luscher, T. F.; Noll, G. Acute heart transplant rejection due to Saint John's wort. Lancet 2000, 355 (9203), 548-549. (Pubitemid 30088678)
30. Tsuji, A. Transporter-mediated Drug Interactions. Drug Metab. Pharmacokinet. 2002, 17 (4), 253-274.
31. Critchfield, J. W.; Welsh, C. J.; Phang, J. M.; Yeh, G. C. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem. Pharmacol. 1994, 48 (7), 1437-1445.
32. Chieli, E.; Romiti, N.; Cervelli, F.; Tongiani, R. Effects of flavonols on P-glycoprotein activity in cultured rat hepatocytes. Life Sci. 1995, 57 (19), 1741-1751.
33. Borska, S.; Sopel, M.; Chmielewska, M.; Zabel, M.; Dziegiel, P. Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin. Molecules 2010, 15 (2), 857-870.
34. Shapiro, A. B.; Ling, V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem. Pharmacol. 1997, 53 (4), 587-596. (Pubitemid 27149553)
35. Piscitelli, S. C.; Burstein, A. H.; Chaitt, D.; Alfaro, R.M.; Falloon, J. Indinavir concentrations and St John's wort. Lancet 2000, 355 (9203), 547-548. (Pubitemid 30088677)
36. Henderson, L.; Yue, Q. Y.; Bergquist, C.; Gerden, B.; Arlett, P. St John's wort (Hypericum perforatum): Drug interactions and clinical outcomes. Br. J. Clin. Pharmacol. 2002, 54 (4), 349-356. (Pubitemid 35334946)
37. Roby, C. A.; Anderson, G. D.; Kantor, E.; Dryer, D. A.; Burstein, A. H. St John's Wort: Effect on CYP3A4 activity. Clin. Pharmacol. Ther. 2000, 67 (5), 451-457. (Pubitemid 30327483)
38. Moore, L. B.; Goodwin, B.; Jones, S. A.; Wisely, G. B.; Serabjit- Singh, C. J.; Willson, T. M.; Collins, J. L.; Kliewer, S. A. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. U.S.A. 2000, 97 (13), 7500-7502. (Pubitemid 30431492)